GRI Bio GRI 深 沪
已收盘 10-02 16:00:00 美东时间
1.96
0.000
0.00%
华盛通- 最 高2.02
- 今 开2.00
- 成交量 4.15万股
- 最 低 1.95
- 昨 收 1.96
- 总市值 428.48万
- 52周最高 64.12
- 市盈率 静 --
- 换手率 1.90%
- 52周最低 1.36
- 委 比 65.10%
- 总股本 218.61万
- 历史最高 64792072.80
- 量 比 0.82
- 振 幅 3.57%
- 历史最低 1.95
- 每 手 1
- 风险率 19.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATED: Watching GRI Bio; Zacks Investment Research Upgrades Stock To Buy
https://www.zacks.com/stock/news/2989341/gri-bio-inc-gri-upgraded-to-buy-what-does-it-mean-for-the-stock
09-14 23:47
美股大行评级 | 齐声看好医药股！礼来、强生、默沙东目标价均获上调；小摩大幅上调Meta目标价至820美元
今日重点评级关注：康托·菲茨杰拉德：维持SOL Strategies"超配"评级，目标价从2.8美元升至6.2美元；康托·菲茨杰拉德：维持Sui Group Holdings"超配"评级，目标价从1.7美元升至3.4美元
09-11 14:30
HC Wainwright & Co. Reiterates Buy on GRI Bio, Maintains $10 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates GRI Bio (NASDAQ:GRI) with a Buy and maintains $10 price target.
09-11 01:24
GRI Bio Reports Positive Phase 2a IPF Biomarker Data
The latest update is out from GRI Bio ( ($GRI) ). On September 8, 2026, GRI Bio...
09-08 20:47
GRI Bio Featured in "Why Now" On-Demand Video Webcast
GRI Bio, Inc. (NASDAQ: GRI) has announced its participation in a "Why Now" video webcast, where CEO Marc Hertz discusses GRI-0621, a once-daily oral RARβ/γ-selective agonist for idiopathic pulmonary fibrosis (IPF). The webcast highlights GRI-0621's mechanism of action and the unmet need for IPF patients. GRI Bio will present data at the 2026 European Respiratory Society Congress in Barcelona, supporting GRI-0621's potential to address IPF's under...
08-27 13:01
GRI Bio shares are trading higher after the company announced three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at ERS Congress 2026.
GRI Bio shares are trading higher after the company announced three abstracts and an oral presentation highlighting data from the Phase 2a GRI-0621-IPF-02 study have been selected for presentation at ERS Congress 2026.
08-24 22:36
GRI Bio to Present Late-Breaking Phase 2a GRI-0621 Data Highlighting Lung Function, Anti-Fibrotic Biomarkers and Favorable Tolerability in IPF at ERS 2026
GRI Bio announced that three abstracts and an oral presentation from its Phase 2a GRI-0621-IPF-02 study will be presented at the 2026 European Respiratory Society Congress in Barcelona. The presentations will focus on the safety, translational biomarkers, and lung function impact of GRI-0621, an oral RARβ/γ-selective agonist for idiopathic pulmonary fibrosis (IPF). CEO Marc Hertz highlighted the encouraging signals supporting GRI-0621's potential...
08-24 13:05
GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung Disease
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company developing innovative therapies for infl...
06-18 20:34
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元
06-02 16:25
